<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Profile</title>
	<atom:link href="http://www.tapanray.in/tag/profile/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Access To Comprehensive Healthcare Merits Multipronged Approach</title>
		<link>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-comprehensive-healthcare-merits-multipronged-approach</link>
		<comments>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/#comments</comments>
		<pubDate>Mon, 10 Dec 2018 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[band-aid]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Gordian]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[knot]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[multi-pronged]]></category>
		<category><![CDATA[multifactorial]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9296</guid>
		<description><![CDATA[Since the turn of the new millennium, several high profile and flagship health schemes are being announced in India by the Union successive governments. Some of the important ones will include the National Health Mission, Rashtriya Swasthya Bima Yojana (RSBY) - a Health &#8230; <a href="http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Hype of Digitalization in Pharma Marketing</title>
		<link>http://www.tapanray.in/the-hype-of-digitalization-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-hype-of-digitalization-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/the-hype-of-digitalization-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 13 Aug 2018 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Automation]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intervention]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transform]]></category>
		<category><![CDATA[transformative]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9095</guid>
		<description><![CDATA[Having access to the fountain of knowledge residing in the cyberspace, fueled by word of mouth information and aided by social media, patients’ behavior is fast changing globally. Its degree may vary. But the change is real. The good news &#8230; <a href="http://www.tapanray.in/the-hype-of-digitalization-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-hype-of-digitalization-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India &#8211; Young Today, Old Tomorrow: Emerging Issues of Aging, Health and Socioeconomic Profile of the Country</title>
		<link>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country</link>
		<comments>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/#comments</comments>
		<pubDate>Sun, 29 Apr 2012 01:30:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Today]]></category>
		<category><![CDATA[Tomorrow]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Young]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=100</guid>
		<description><![CDATA[‘World Health Day’ is celebrated every year on April 7, the day ‘World Health Organization (WHO)’ was founded in 1948. Each year, on this day, people from all walks of life across the globe are invited by WHO to focus &#8230; <a href="http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Disruptive Innovation in Healthcare &#8211; Personalized Medicines</title>
		<link>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-disruptive-innovation-in-healthcare-personalized-medicines</link>
		<comments>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 01:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Personalized. Medicines]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=287</guid>
		<description><![CDATA[Tufts Center for the Study of Drug Development (Tufts University) in its publication named ‘Impact Report’, November/December 2010 articulated, “Biopharmaceutical companies are committed to researching and developing personalized medicines and within their development pipelines, 12%-50% of compounds are personalized medicines.” &#8230; <a href="http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
